Wipfli Financial Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Wipfli Financial Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$13K	Buy	+56	New	+$11.3K	﹤0.01%	1764

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wipfli Financial Advisors's KRTX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2022: 56 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1764 among its holdings.

257 funds tracked by Wall St. Rank hold KRTX as of Q3 2022.

Wipfli Financial Advisors held 56 shares of Karuna Therapeutics, Inc. Common Stock worth $13K as of Q3 2022.
Karuna Therapeutics, Inc. Common Stock was a new Wipfli Financial Advisors position in Q3 2022.
Karuna Therapeutics, Inc. Common Stock made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1764 holding.
257 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.